Oral Live-Carrier Vaccine of Recombinant Lactococcus Lactis Inducing Prophylactic Protective Immunity Against Helicobacter Pylori Infection

Overview

Journal Probiotics Antimicrob Proteins

Publisher Springer

Specialties Infectious Diseases
Microbiology
Nutritional Sciences
Pharmacology

Date 2024 Sep 9

PMID 39251521

Authors

Xiumei Ni

Yu Liu

Min Sun

Yajun Jiang

Yi Wang

Dingxin Ke

Gang Guo

Kaiyun Liu

Affiliations

Soon will be listed here.

Abstract

Helicobacter pylori infects the gastric mucosa and induces chronic gastritis, peptic ulcers, and gastric cancer. Research has demonstrated that vaccination can induce a protective immune response and prevent H. pylori infection. Oral administration of the Lactococcus lactis live-carrier vaccine is safe and easily complied with by the public. In this study, two recombinant L. lactis strains were constructed that expressed antigens of H. pylori urease subunit alpha (UreA) and UreA fused with Escherichia coli heat-labile toxin B subunit (LTB-UreA), named LL-UreA and LL-LTB-UreA, respectively. The expression of antigen proteins was confirmed by Western blotting analysis. Survival assessment indicated that the engineered L. lactis could colonize in the digestive tract of BALB/c mice up to 10 days after the last oral administration with our immunization protocol. The ability to induce immune response and immune protective efficacy of the L. lactis were confirmed. These results indicated that oral administration with LL-UreA or LL-LTB-UreA could induce UreA-specific mucosal secretory IgA (sIgA) and cellular immune response, significantly increasing the cytokines levels of interferon-gamma (IFN-γ), interleukin (IL)-17A, and IL-10, together with the proportion of CD4IFN-γ T cells and CD4IL17A T cells. More importantly, oral administration of LL-UreA and LL-LTB-UreA brought about effective protection in mice to prevent H. pylori infection, especially LL-UreA, resulting in 70% of mice showing no H. pylori colonization and the remaining 30% showing only low levels of colonization. These findings underscore the potential of using orally administered engineered L. lactis vaccines to prevent H. pylori infection.

References

Mirzaei N, Poursina F, Moghim S, Rashidi N, Safaei H . The study of H. pylori putative candidate factors for single- and multi-component vaccine development. Crit Rev Microbiol. 2017; 43(5):631-650. DOI: 10.1080/1040841X.2017.1291578. View

Best L, Takwoingi Y, Siddique S, Selladurai A, Gandhi A, Low B . Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018; 3:CD012080. PMC: 6513531. DOI: 10.1002/14651858.CD012080.pub2. View

Xu W, Xu L, Xu C . Relationship between infection and gastrointestinal microecology. Front Cell Infect Microbiol. 2022; 12:938608. PMC: 9433739. DOI: 10.3389/fcimb.2022.938608. View

Liou J, Malfertheiner P, Lee Y, Sheu B, Sugano K, Cheng H . Screening and eradication of for gastric cancer prevention: the Taipei global consensus. Gut. 2020; 69(12):2093-2112. DOI: 10.1136/gutjnl-2020-322368. View

Yan L, Chen Y, Chen F, Tao T, Hu Z, Wang J . Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report From a Randomized Controlled Trial With 26.5 Years of Follow-up. Gastroenterology. 2022; 163(1):154-162.e3. DOI: 10.1053/j.gastro.2022.03.039. View

Malfertheiner P, Selgrad M, Wex T, Romi B, Borgogni E, Spensieri F . Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. Lancet Gastroenterol Hepatol. 2018; 3(10):698-707. DOI: 10.1016/S2468-1253(18)30125-0. View

Graham D, Miftahussurur M . urease for diagnosis of infection: A mini review. J Adv Res. 2018; 13:51-57. PMC: 6077137. DOI: 10.1016/j.jare.2018.01.006. View

Zeng M, Mao X, Li J, Tong W, Wang B, Zhang Y . Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386(10002):1457-64. DOI: 10.1016/S0140-6736(15)60310-5. View

Hifumi E, Yamada Y, Uda T . A catalytic antibody heavy chain HpU-2 degrading its epitope peptide and H. pylori urease. Immunol Lett. 2005; 103(1):68-74. DOI: 10.1016/j.imlet.2005.10.016. View

10.

Guo L, Liu K, Xu G, Li X, Tu J, Tang F . Prophylactic and therapeutic efficacy of the epitope vaccine CTB-UA against Helicobacter pylori infection in a BALB/c mice model. Appl Microbiol Biotechnol. 2012; 95(6):1437-44. DOI: 10.1007/s00253-012-4122-0. View

11.

Song H, Lv X, Yang J, Liu W, Yang H, Xi T . A novel chimeric flagellum fused with the multi-epitope vaccine CTB-UE prevents Helicobacter pylori-induced gastric cancer in a BALB/c mouse model. Appl Microbiol Biotechnol. 2015; 99(22):9495-502. DOI: 10.1007/s00253-015-6705-z. View

12.

Da Hora V, Conceicao F, Dellagostin O, Doolan D . Non-toxic derivatives of LT as potent adjuvants. Vaccine. 2010; 29(8):1538-44. DOI: 10.1016/j.vaccine.2010.11.091. View

13.

Zerna G, Rathinasamy V, Toet H, Anderson G, Dempster R, Spithill T . Evaluation of Immunogenicity and Efficacy of Tetraspanin 2 (TSP2) Fused to Heat-Labile Enterotoxin B Subunit LTB Adjuvant Following Intranasal Vaccination of Cattle. Vaccines (Basel). 2021; 9(11). PMC: 8623123. DOI: 10.3390/vaccines9111213. View

14.

Sharma M, Dash P, Sahoo P, Dixit A . Th2-biased immune response and agglutinating antibodies generation by a chimeric protein comprising OmpC epitope (323-336) of Aeromonas hydrophila and LTB. Immunol Res. 2017; 66(1):187-199. DOI: 10.1007/s12026-017-8953-8. View

15.

Guo L, Zhang F, Wang S, Li R, Zhang L, Zhang Z . Oral Immunization With a M Cell-Targeting Recombinant Vaccine LL-plSAM-FVpE Stimulate Protective Immunity Against in Mice. Front Immunol. 2022; 13:918160. PMC: 9336465. DOI: 10.3389/fimmu.2022.918160. View

16.

DiPetrillo M, Tibbetts T, Kleanthous H, Killeen K, Hohmann E . Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine. 1999; 18(5-6):449-59. DOI: 10.1016/s0264-410x(99)00246-7. View

17.

Azegami T, Yuki Y, Kiyono H . Challenges in mucosal vaccines for the control of infectious diseases. Int Immunol. 2014; 26(9):517-28. DOI: 10.1093/intimm/dxu063. View

18.

Song A, In L, Lim S, Rahim R . A review on Lactococcus lactis: from food to factory. Microb Cell Fact. 2017; 16(1):55. PMC: 5379754. DOI: 10.1186/s12934-017-0669-x. View

19.

Levit R, Cortes-Perez N, de Moreno de LeBlanc A, Loiseau J, Aucouturier A, Langella P . Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health. Gut Microbes. 2022; 14(1):2110821. PMC: 9377234. DOI: 10.1080/19490976.2022.2110821. View

20.

Shirdast H, Ebrahimzadeh F, Taromchi A, Mortazavi Y, Esmaeilzadeh A, Sekhavati M . Recombinant Lactococcus Lactis Displaying Omp31 Antigen of Brucella melitensis Can Induce an Immunogenic Response in BALB/c Mice. Probiotics Antimicrob Proteins. 2020; 13(1):80-89. DOI: 10.1007/s12602-020-09684-1. View